Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179049 | 0.89 | AGER (0.44) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL116604 | 0.88 | AGER (0.41) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL116676 | 0.88 | AGER (0.41) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL2823373 | 0.87 | AGER (0.43) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL29958689 | 0.87 | AGER (0.43) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL2941601 | 0.86 | AGER (0.42) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL499843 | 0.85 | CA12 (0.42) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL25345480 | 0.84 | AGER (0.41) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL30802773 | 0.84 | AGER (0.41) | AGERGAASTAT3ALDH1A1CYP3A4 | |
| SCHEMBL20267914 | 0.84 | GAA (0.42) | AGERGAASTAT3ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116231075-A | Electrolyte containing overcharge-preventing additive and lithium ion battery | 湖北亿纬动力有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-105461708-A | Quinazoline tyrosine kinase inhibitor, and preparation method and application thereof | SHANGHAI SUN-SAIL PHARMACEUTICAL SCIENCE & TECH CO LTD | 2016-04-06 | — | — | CN | claimed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4620954-A1 | CDK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shandong Luye Pharmaceutical Co., Ltd. (CN) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025087431-A1 | PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES | 贝达药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-20250136582-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250105357-A1 | ELECTROLYTE SOLVENTS AND METHODS FOR LITHIUM METAL AND LITHIUM ION BATTERIES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-03-27 | — | — | US | disclosed |
| WO-2025056068-A1 | BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海济煜医药科技有限公司 | 2025-03-20 | — | — | WO | disclosed |
| US-12240825-B2 | Oxexin 1 receptor antagonists | NXERA PHARMA UK LIMITED (GB) | 2025-03-04 | — | — | US | disclosed |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-01-30 | — | — | US | disclosed |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-11-19 | — | — | US | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1691777-A2 | NOVEL DIFFERENTIAL IMAGING METHOD | Medi-Physics, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| WO-2005053615-A9 | NOVEL DIFFERENTIAL IMAGING METHOD | MEDI PHYSICS INC (US) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005053615-A2 | NOVEL DIFFERENTIAL IMAGING METHOD | MEDI-PHYSICS, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-0517041-A1 | New Cephem Compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136582-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | AGER 2901/4885GAA 1443/4885STAT3 777/4885 |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | EED, EEF1D, EEF1A1 | AGER 4404/4885GAA 3003/4885STAT3 2981/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | AGER 1375/4885GAA 4200/4885STAT3 4642/4885 |
| US-12240825-B2 | Oxexin 1 receptor antagonists | HCRTR1, HCRTR2, OXTR | AGER 1760/4885GAA 3739/4885STAT3 3257/4885 |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | AGER 4404/4885GAA 3003/4885STAT3 2981/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | AGER 4201/4885GAA 4300/4885STAT3 2443/4885 |
| US-20250105357-A1 | ELECTROLYTE SOLVENTS AND METHODS FOR LITHIUM METAL AND LITHIUM ION BATTERIES | LEF1, MLEC, LAGE3 | AGER 3262/4885GAA 4050/4885STAT3 110/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | AGER 1375/4885GAA 4200/4885STAT3 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.